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Abstract
Background: The atrial fibrillation (AF) associated microRNAs (miRNAs) were found in the right atrium (RA) and left
atrium (LA) from patients with rheumatic mitral valve disease (RMVD). However, most studies only focus on the RA;
and the potential differences of AF-associated miRNAs between the RA and LA are still unknown. The aim of this
study was to perform miRNA expression profiles analysis to compare the potential differences of AF-associated
miRNAs in the right atrial appendages (RAA) and left atrial appendages (LAA) from RMVD patients.
Methods: Samples tissues from the RAA and LAA were obtained from 18 RMVD patients (10 with AF) during mitral
valve replacement surgery. From these tissues, miRNA expression profiles were created and analyzed using a
human miRNA microarray. Then, the results were validated using qRT-PCR analysis for 12 selected miRNAs. Finally,
potential targets of 10 validated miRNAs were predicted and their functions and potential pathways were analyzed
using the miRFocus database.
Results: In RAA, 65 AF-associated miRNAs were found and significantly dysregulated (i.e. 28 miRNAs were up-regulated
and 37 were down-regulated). In LAA, 42 AF-associated miRNAs were found and significantly dysregulated (i.e. 22 miRNAs
were up-regulated and 20 were down-regulated). Among these AF-associated miRNAs, 23 of them were found in both
RAA and LAA, 45 of them were found only in RAA, and 19 of them were found only in LAA. Finally, 10 AF-associated
miRNAs validated by qRT-PCR were similarly distributed in RAA and LAA; 3 were found in both RAA and LAA, 5 were
found only in RAA, and 2 were found only in LAA. Potential miRNA targets and molecular pathways were
identified.
Conclusions: We have found the different distributions of AF-associated miRNAs in the RAA and LAA from RMVD
patients. This may reflect different miRNA mechanisms in AF between the RA and LA. These findings may provide
new insights into the underlying mechanisms of AF in RMVD patients.
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Atrial fibrillation (AF) is the most common sustained
arrhythmia in clinical practice and it is associated with
pronounced morbidity, mortality, and socio-economic
burden [1]. Effective therapy and prevention is crucial
for the control of AF-related morbidity and mortality.
However, to date, medical interventions for AF are rela-
tively limited, because the precise mechanisms of AF
have not been completely elucidated. Therefore, new
methods leading to further insights into the underlying
mechanisms of AF and potential novel mechanism-
based therapeutic strategies are required [2].
MicroRNAs (miRNAs) are emerging as new regulators
of gene expression at the post-transcriptional level and
are shedding new light on the regulatory mechanisms
underlying AF [3]. miRNAs are small, endogenous,
single-stranded, non-coding RNAs of ∼22 nucleotides
that bind target sequences in the 3′-untranslated region
of target genes to induce mRNA instability or to inhibit
translation [4]. Studies have shown that miRNAs regu-
late key genetic functions in cardiovascular biology and
play an important role in the pathogenesis of cardiac
diseases including cardiac development [5], cardiac
hypertrophy/heart failure [6], myocardial infarction [7],
myocardial ischemia-reperfusion injury [8], and arrhyth-
mogenesis [9]. Recently, there are many studies indicat-
ing that miRNAs are involved in AF through their target
genes [10-13].
AF often occurs concomitantly with other cardiovas-
cular diseases such as hypertension, coronary artery dis-
ease, congestive heart failure, and valvular heart disease
[14]. AF is also prevalent in rheumatic mitral valve dis-
ease (RMVD) [15]. RMVD is a major cardiovascular dis-
ease in developing countries where rheumatic fever is
less well controlled, and is also a major clinical risk fac-
tor for AF [16]. Remodeling of the right atrium (RA)
and left atrium (LA) associated with AF in RMVD pa-
tients are well established [17]. Studies have shown that
miRNAs may be involved directly or indirectly in AF by
modulating atrial remodelling [18]. Recently, the AF-
associated miRNAs were respectively found in RA [19]
and LA [20] from RMVD patients.
Morphological [21] and electrophysiological [17] dif-
ferences have been demonstrated between the RA and
LA, which at least in part, may reflect different mecha-
nisms involved in AF between the RA and LA [22].
Thus, it is not surprising that AF-associated miRNAs of
the RA may differ from those of the LA. However, most
studies of AF-associated miRNAs focus on the RA; and
the potential difference of AF-associated miRNAs be-
tween RA and LA are still unknown.
Thus, the aim of this study was to analyze miRNA ex-
pression profiles to compare the potential differences of
AF-associated miRNAs in the RA and LA from RMVD
patients who were either in an sinus rhythm (SR) or AF
group.
Methods
Approval was obtained from the human ethics committee
of the first affiliated hospital of Sun Yat-sen University. The
investigation complied with the principles that govern
the use of human tissues outlined in the Declaration of
Helsinki. All patients gave informed consent before partici-
pating in the study.
Human tissue preparation
Tissue samples from the right atrial appendage (RAA)
and left atrial appendage (LAA) were obtained from18
RMVD patients. 8 patients were in SR group and they
did not have a history of AF; 10 patients were in AF
group and they had documented arrhythmia for more
than six months before surgery. The tissue samples were
obtained at the time of the mitral valve replacement sur-
gery, immediately snap frozen in liquid nitrogen, and
stored at −80°C until used. The diagnosis of AF was
made based on medical records and 12-lead electrocar-
diogram (ECG) findings. Patients with SR had no history
of using antiarrhythmic drugs and were screened to ensure
that they had never experienced AF [23]. Pre-operative
color Doppler echocardiography was performed routinely
on the patients. Preoperative functional status was
recorded according to the New York Heart Association
(NYHA) classifications.
RNA isolation
Total RNA was extracted from human tissue samples
(RAA and LAA) using TRIzol reagent (Invitrogen) accord-
ing to the manufacturer’s protocol. The RNA quality of
each sample was determined using an Agilent 2100 Bioana-
lyzer (Agilent Technologies; Santa Clara, CA, USA) and the
sample was immediately stored at −80°C.
MiRNA microarray processing and analysis
The miRNA microarray was processed by LC Sciences
(Houston, TX, USA) as described previously [20]. In
brief, the assay utilized 2 to 5 μg total RNA sample. The
total RNA was size fractionated using a YM-100 Micro-
con centrifugal filter (Millipore, Billerica, MA) and RNA
sequences with <300 nt were isolated. These small RNA
were then extended at 3′-end with a poly(A) tail using
poly(A) polymerase, followed by ligation of an oligo-
nucleotide tag to the poly(A) tail for later fluorescent
dye staining. Hybridization was performed overnight on
a μParaflo™ microfluidic chip using a micro-circulation
pump (Atactic Technologies, Inc, Houston, TX). Each
microfluidic chip contained detection probes and control
probes. The detection probes were made in situ by
photogenerated reagent (PGR) chemistry. These probes
Liu et al. Journal of Translational Medicine 2014, 12:90 Page 2 of 12
http://www.translational-medicine.com/content/12/1/90consisted of a chemically modified nucleotide coding se-
quence complementary to the target microRNA (all 1,921
human miRNAs listed in the Sanger’sm i R N A m i R B a s e ,
Release 18.0, http://microrna.sanger.ac.uk/sequences/) and
a spacer segment of polyethylene glycol to extend the cod-
ing sequences away from the substrate. The hybridization
melting temperatures were balanced by chemical modifica-
tions of the detection probes. Hybridization was performed
using 100 μL of 6× SSPE buffer (0.90 M NaCl, 60 mM
Na2HPO4, 6 mM EDTA, pH 6.8) containing 25% formam-
ide at 34°C. Fluorescence labeling with tag specific Cy5
dye was used for after-hybridization detection. An Axon
GenePix 4000B Microarray Scanner (Molecular Device,
Union City, CA) was used to collect the fluorescent images,
which were then digitized using Array-Pro Image Analysis
software (Media Cybernetics, Bethesda, MD). Each miRNA
was analyzed two times and the controls were repeated
4–16 times.
The miRNA microarray analysis was also performed
at LC Sciences. The microarray data were analyzed by
subtracting the background and then the signals were
normalized using a locally weighed regression (LOW-
ESS) filter as reported previously [24]. Detectable miR-
NAs were selected based on the following criteria: signal
intensity higher than 3× the background standard deviation
and spot CV < 0.5 (where CV =standard deviation/signal
intensity). When repeating probes were present on an array,
a transcript was listed as detectable only if the signals from
at least 50% of the repeating probes were above detection
level. To identify miRNAs whose expression differs
among the groups, statistic analysis was performed and the
P-values of the t-test were also calculated. The ratio of two
samples was calculated and expressed in log2
scale (balanced) for
each miRNA. The miRNAs were then sorted according to
their differential ratios.
Quantitative real-time PCR (qRT-PCR) of miRNA expression
To validate the microarray results in the study, a stem-
loop qRT-PCR based on SYBR Green I was performed
on differentially expressed miRNAs. The primers used
are listed in Additional file 1. Total RNA was isolated
using the TRIzol Reagent (Invitrogen) as previously de-
scribed. A single-stranded cDNA for a specific miRNA
was generated by reverse transcription of 250 ng of total
RNA using a miRNA-specific stem-looped RT primer.
Briefly, a reverse transcription reaction mixture con-
tained 250 ng of total RNA, 0.5 μlo f2μM stem-loop
RT primer, 1.0 μl of 5× RT buffer, 0.25 μl of 10 mM each
dNTPs, 0.25 μlo f4 0U / μlRNase inhibitor and 0.5 μl
of 200 U/μl M-MLV. An Eppendorf Mastercycler®
(Eppendorf, Hamburg, Germany) was used to conduct
the reverse transcription reaction at the following
temperature conditions: 42°C for 60 min, 70°C for
15 min and finally held at 4°C.
Following the reverse transcription reaction, qRT-PCR
was performed using an ABI PRISM® 7900HT sequence-
detection system (Applied Biosystems, Foster City, CA,
USA) with the Platinum SYBR Green qPCR SuperMix-
UDG (Invitrogen). According to the manufacturer’s in-
structions, the PCR reaction (a total of 20 μl) contained
0.5 μl of RT product, 10 μl of 2× SYBR Green Mix,
0.4 μl of ROX, 0.8 μlo f1 0μM primer mix, and 8.3 μlo f
nuclease-free water. The reaction protocol was as fol-
lows: 95°C for 2 min, followed by 40 amplification cycles
of 95°C for 15 s, and 60°C for 30 s.
In qRT-PCR analysis, the relative expression level for
each miRNA was calculated using a comparative cycle
threshold 2
-ΔΔCt method for three independent experi-
ments [25]. RNU6B was used as an internal control for
normalizing the results.
Target prediction and function analysis
We used the human miRNA information database miR-
Focus (http://mirfocus.org/ Version 2.1) to predict po-
tential human miRNA target genes. The miRFocus
provides a full gene description and functional analysis
for each target gene by combining the predicted target
genes from other databases (TargetScan, miRanda, Pic-
Tar, MirTarget and microT). The greater the number of
databases predicting that a gene would be a target, the
more likely the miRNA-mRNA interaction would be
relevant [26]. In this study, we have included genes that
were predicted by two or more databases. The miRFocus
program also identifies miRNA-enriched pathways, in-
corporating those from the Kyoto Encyclopedia of Genes
and Genomes (KEGG), Biocarta, and Gene Ontology
(GO) databases, using Fisher’s exact test.
Statistical analyses
All data are presented as mean ±standard deviation and
analyzed by paired t-test. For microarray results, miRNAs
with P-values < 0.1 and |log2
ratio|> 0 . 5w e r ec o n s i d e r e dt o
be significantly differentially expressed, while P <0 . 05w as
considered statistically significant for qRT-PCR analysis.
Results
Clinical characteristics of the SR and AF patients
Tissues from both RAA and LAA were obtained from
each patient.There were no significant differences in
terms of age, gender or NYHA classifications between
the SR and AF groups. Pre-operative color Doppler
echocardiography showed that the LA size of the pa-
tients with AF was significantly greater than patients
with SR as previously reported [27]. There were no dif-
ferences in the left ventricular ejection fraction (LVEF)
between the groups (Table 1).
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Of the 1,898 human miRNAs analyzed, a total of 258
miRNAs were detected (in SR-RAA, SR-LAA, AF-RAA,
or AF-LAA). In the SR-RAA, SR-LAA, AF-RAA, and
AF-LAA groups 164, 155, 216, and 208 miRNAs were
expressed, respectively (Figure 1A). Among these, 132
miRNAs were detected in all groups. A number of miR-
NAs were expressed only in one of the four groups—6
in the SR-RAA group, 2 in the SR-LAA group, 40 in the
AF-RAA group, and 19 in the AF-LAA group.
Among the 258 miRNAs, 178 miRNAs were expressed in
SR patients (SR-RAA or SR-LAA), while 250 miRNAs were
expressed in AF patients (AF-RAA or AF-LAA). AF re-
sulted in greater expression of miRNAs than SR (Figure 1B).
A total of 235 miRNAs were expressed in RAA tissues (SR-
RAA or AF-RAA), while 213 miRNAs were expressed in
LAA tissues (SR-LAA or AF-LAA). RAA tissues had a lar-
ger number of miRNAs expressed (Figure 1C).
For most of the detected miRNAs, the expression levels
were low, which was evident by their low signal intensities
(less than 500 units) during microarray analysis (Figure 2).
Of the 164 miRNAs detected in SR-RAA tissues, 88
miRNAs emitted signals less than 500 units, while only 8
miRNAs produced signals above 10,000 units. Of the 155
miRNAs detected in SR-LAA tissues, 86 miRNAs emit-
ted signals less than 500 units, while only 5 miRNAs
produced signals above 10,000 units. Of the 216
miRNAs detected in AF-RAA tissues, 106 miRNAs
emitted signals less than 500 units, while only 7
miRNAs produced signals above 10,000 units. Of the
2 0 8m i R N A sd e t e c t e di nA F - L A At i s s u e s ,1 2 9p r o d u c e d
signals below 500 units, while only 3 produced signals
above 10,000 units.
The signal intensities of the miRNAs expressed in only
one of the four groups were not high enough to consider
them differentially expressed among groups, and hence
were not be considered for further analysis.
Table 1 Clinical characteristics of the SR and AF patients
SR (n = 8) AF (n = 10)
Gender (male/female) 5/3 5/5
Age (years) 50.16±6.88 51.42±7.12
LA size (mm) 43.31±3.23 57.65±5.08*
LVEF (%) 61.34±5.66 58.71±3.81
NYHA class II (6/8) / III (2/8) II (7/10) / III (3/10)
*P < 0.05 (comparing to the SR patients).
Figure 1 The numbers of miRNAs detected in SR-RAA, SR-LAA,
AF-RAA and AF-LAA using miRNA microarray assay. (A) A total of
258 miRNAs were detected (in SR-RAA, SR-LAA, AF-RAA, or AF-LAA). In
the SR-RAA, SR-LAA, AF-RAA, and AF-LAA groups 164, 155, 216, and 208
miRNAs were expressed, respectively. (B) 178 miRNAs were expressed in
SR patients (SR-RAA or SR-LAA), while 250 miRNAs were expressed in AF
patients (AF-RAA or AF-LAA). (C) 235 miRNAs were expressed in RAA
tissues (SR-RAA or AF-RAA), while 213 miRNAs were expressed in LAA
tissues (SR-LAA or AF-LAA).
Figure 2 Signal distributions of all detected miRNAs in SR-RAA,
SR-LAA, AF-RAA and AF-LAA. The signal intensities of most of
these miRNAs were low (0–500 units), with only 23 miRNAs showing
intensities greater than 10000 units.
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The SR-RAA group expressed 164 miRNAs, while the
AF-RAA group expressed 216 miRNAs. Along with the
number of detectable miRNAs, the expression levels of
these miRNAs were also significantly different. Statistical
analysis showed that 65 of these miRNAs were significantly
dysregulated between AF-RAA and SR-RAA. Among these
AF-associated miRNAs, 28 were up-regulated and 37 were
down-regulated (Table 2 and Figure 3A).
miRNA expression profiles changes associated with AF in
LAA tissue
The SR-LAA group expressed 155 miRNAs, while the AF-
LAA group expressed 208 miRNAs. Along with the num-
ber of detectable miRNAs, significant differences also
existed in the expression levels of these miRNAs. Statistical
analysis showed that 42 miRNAs were significantly dysreg-
ulated in AF-LAA relative to SR-LAA. Among these AF-
Table 2 miRNA expression differences between AF-RAA
and SR-RAA
miRNA SR-RAA
signal
AF-RAA
signal
Log2
(AF-RAA/SR-RAA) P-value
Up-regulated (n = 28*)
hsa-miR-4687-3p 378 1654 2.13 3.86E-02
hsa-miR-4485 119 518 2.12 6.98E-02
hsa-miR-4484 879 3609 2.04 5.09E-02
hsa-miR-762 142 544 1.94 4.24E-02
hsa-miR-3940-5p 489 1740 1.83 6.45E-02
hsa-miR-149-3p 107 373 1.81 7.71E-02
hsa-miR-4707-5p 371 1295 1.80 6.57E-02
hsa-miR-4281 480 1524 1.67 2.85E-02
hsa-miR-574-5p 279 883 1.66 6.56E-02
hsa-miR-1281 229 713 1.64 2.26E-02
hsa-miR-3141 883 2687 1.60 4.32E-02
hsa-miR-4488 1049 2915 1.47 7.12E-02
hsa-miR-1973 876 2203 1.33 5.07E-02
hsa-miR-4463 241 587 1.28 5.99E-02
hsa-miR-4505 213 504 1.24 3.66E-02
hsa-miR-4466 1286 3026 1.23 5.73E-02
hsa-miR-940 280 629 1.17 8.74E-02
hsa-miR-4459 2647 5576 1.08 8.57E-02
hsa-miR-2861 1081 2265 1.07 4.66E-02
hsa-miR-4534 105 208 0.99 4.21E-02
hsa-miR-3656 2615 5009 0.94 8.13E-02
hsa-miR-4530 2265 4225 0.90 4.38E-02
hsa-miR-4443 182 326 0.84 2.88E-02
hsa-miR-4284 159 276 0.80 5.12E-02
hsa-miR-4508 1836 2991 0.70 2.36E-02
hsa-miR-1915-3p 1805 2917 0.69 2.12E-02
hsa-miR-4298 1478 2314 0.65 8.97E-02
hsa-miR-4497 3651 5392 0.56 6.18E-02
Down-regulated (n =37*)
hsa-miR-451a 2775 97 −4.83 3.47E-02
hsa-miR-29a-3p 778 156 −2.32 5.04E-02
hsa-miR-99a-5p 645 162 −1.99 5.83E-02
hsa-miR-25-3p 386 101 −1.93 4.99E-02
hsa-miR-486-5p 632 167 −1.92 5.85E-02
hsa-miR-16-5p 683 186 −1.88 2.05E-02
hsa-miR-455-3p 220 61 −1.85 5.70E-02
hsa-miR-222-3p 389 116 −1.75 1.34E-02
hsa-miR-195-5p 902 290 −1.64 5.19E-02
hsa-miR-221-3p 252 82 −1.62 1.13E-02
hsa-miR-22-3p 302 104 −1.54 3.02E-02
hsa-miR-331-3p 216 78 −1.47 9.03E-02
hsa-miR-4324 1409 540 −1.38 9.86E-02
Table 2 miRNA expression differences between AF-RAA
and SR-RAA (Continued)
hsa-miR-30c-5p 2822 1107 −1.35 2.87E-02
hsa-miR-378d 171 69 −1.32 8.68E-02
hsa-miR-125a-5p 3506 1488 −1.24 6.63E-02
hsa-miR-151a-5p 622 267 −1.22 5.18E-02
hsa-miR-143-3p 1732 746 −1.22 4.85E-02
hsa-miR-151b 556 253 −1.13 3.69E-02
hsa-miR-4454 1276 582 −1.13 3.42E-02
hsa-miR-145-5p 7284 3352 −1.12 8.73E-02
hsa-miR-378a-3p 477 221 −1.11 8.70E-02
hsa-miR-30b-5p 1857 869 −1.10 5.33E-02
hsa-miR-26b-5p 1342 638 −1.07 5.00E-02
hsa-miR-133b 3912 1868 −1.07 9.81E-02
hsa-miR-107 592 284 −1.06 3.95E-02
hsa-miR-152 293 141 −1.05 7.94E-02
hsa-miR-30a-5p 409 201 −1.03 2.72E-02
hsa-miR-125b-5p 7602 3820 −0.99 7.43E-02
hsa-miR-4286 243 128 −0.92 8.45E-02
hsa-miR-191-5p 1441 767 −0.91 7.19E-02
hsa-miR-26a-5p 9621 5219 −0.88 6.04E-02
hsa-miR-21-5p 633 351 −0.85 8.92E-03
hsa-miR-30d-5p 1225 692 −0.82 5.79E-02
hsa-miR-5100 458 274 −0.74 8.76E-02
hsa-miR-181a-5p 998 613 −0.70 3.23E-02
hsa-let-7a-5p 16804 10484 −0.68 7.85E-02
*Expression levels of miRNAs are described as up-regulated or down-regulated
in AF-RAA relative to those in SR-RAA.
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down-regulated (Table 3 and Figure 3B)
Comparison of AF-associated miRNAs between RAA and
LAA tissues
A total of 84 AF-associated miRNAs were found (either in
RAA or LAA tissues): 65 AF-associated miRNAs were
found in RAA tissues, while 42 AF-associated miRNAs
were found in LAA tissues. Among these, 23 AF-
associated miRNAs were found both in RAA and LAA,
while 45 AF-associated miRNAs were found only in
RAA, and 19 AF-associated miRNAs were found only
in LAA (Table 4).
Validation of the miRNA microarray data by qRT-PCR
To validate the data obtained from the miRNA micro-
array, qRT-PCR was performed on 12 AF-associated
miRNAs. The AF-associated miRNAs were selected for
further analysis using qRT-PCR based on the following
criteria: at least one group (SR or AF group) had a signal
intensity >1000 units in the RAA or LAA tissues. Finally,
we selected 9 AF-associated miRNAs from RAA
(Figure 4A) and 6 AF-associated miRNAs from LAA
(Figure 4B). Among these: 3 miRNAs (i.e. miR-26a-5p,
miR-143-3p, and miR-4454) were expressed in both
RAA and LAA; 6 miRNAs (i.e. miR-30c-5p, miR-125b-
5p, miR-133b, miR- 145-5p, miR-451a, and miR-4484)
were expressed in only RAA; and 3 miRNAs (i.e. miR-1,
miR-23b-3p, and miR-494) were expressed in only LAA.
According to the qRT-PCR data, miR-26a-5p, miR-
143-3p, miR-4454 were AF-associated miRNAs found
in both RAA and LAA tissues, while miR-30c-5p,
miR-125b-5p, miR-133b, miR-145-5p, miR-4484 were AF-
associated miRNAs found in only RAA tissues and miR-1,
miR-23b-3p were found only in LAA tissues (Figure 5).
Our qRT-PCR data validated the results for all of these
miRNAs except miR-451a and miR-494. miR-451a was an
AF-associated miRNA found only in RAA in the array data
(Table 4), but was neither found in the RAA nor LAA when
assayed using qRT-PCR (Figure 5). miR-494 was AF-
associated miRNA found only in the LAA from the array
data (Table 4), but was neither found in the RAA nor LAA
when assayed using qRT-PCR (Figure 5).
Comparing expression of AF-associated miRNAs in RAA
and LAA tissues from RMVD patients with SR
We identified 10 AF-associated miRNAs using the micro-
array and qRT-PCR techniques. These AF-associated miR-
NAs had different tissue distributions between the RAA
and LAA (Table 4, Figure 5). We wanted to know whether
expressions of these miRNAs were different between the
RAA and LAA tissues based on SR status. So we next com-
pared expression levels of these miRNAs between the SR-
RAA and SR-LAA groups. The expression levels of most of
the AF-associated miRNAs were identical between RAA
and LAA in SR patients, with the exception of miR-23b-3p
and miR-125b-5p (Figure 6A). miR-23b-3p was more highly
e x p r e s s e di nt h eS R - L A Ag r o u pt h a ni nS R - R A A ,a n dm i R -
125b-5p was more highly expressed in the SR-RAA group.
Moreover, we compared the expression level of miR-23b-
3p and miR-125b-5p among four groups (i.e. SR-RAA, SR-
LAA, AF-RAA, and AF-LAA). In LAA tissues, the expres-
sion level of miR-23b-3p was down-regulated in the AF
group relative to the SR group. In RAA tissues, the expres-
sion level of miR-23b-3p did not change between the SR
group and AF group (Figure 6B). Meanwhile, a change in
miR-125b-5p expression between SR and AF groups oc-
curred only in RAA tissues, where miR-125b-5p was more
highly expressed in SR group (Figure 6C).
Prediction of putative target genes and pathways of the
AF-associated miRNAs
To determine the probable biological function of the
AF-associated miRNAs, we predicted the putative targets
and pathways of 10 validated miRNAs (i.e. miR-1, miR-
23b-3p, miR-26a-5p, miR-30c-5p, miR-125b-5p, miR-133b,
miR-143-3p, miR-145-5p, miR-4454, and miR-4484) using
the miRFocus database.
Figure 3 Heat map showing the miRNAs significantly
dysregulated in RAA and LAA tissues. (A) Heat map showing
the expression of dysregulated miRNAs in RAA tissues (AF-RAA vs
SR-RAA). (B) Heat map showing the expression of dysregulated
miRNAs in LAA tissues
(AF-LAA vs SR-LAA).
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diction databases except miR-4454 and miR-4484. miR-
4454 cannot be predicted using 5 target prediction data-
bases, while, miR-4484 can be predicted using 2 target
prediction databases. Numerous putative target genes
and pathways were identified for these miRNAs except
miR-4454. Many of these predicted targets have been ex-
perimentally validated (Table 5, Additional file 2).
The biological function and potential functional path-
ways of each putative gene target were classified using
the GO term and KEGG pathway. Since every gene is as-
sociated with many GO terms and KEGG pathways, the
significant GO term (see Additional file 3) and KEGG
pathway (see Additional file 4) for each miRNA were
identified using Fisher’s exact test. Table 6 gives a few
representative KEGG pathways for the putative target
genes of the validated miRNAs as predicted by the miR-
Focus. The pathway analysis suggested that these miR-
NAs may potentially contribute to AF.
Discussion
Two recent studies investigating expression profiles of
miRNA in mitral stenosis patients found the AF-
associated miRNAs in RA [19] and LA [20], respectively,
many of which were also found in our study. However, the
studies investigated the alterations of miRNA expression
profiles in relation to AF only in RA or LA tissue and
they could not compare the potential differences of AF-
associated miRNAs between the RA and LA. A recent
study investigated changes in miRNA expression profiles in
patients with valvular heart disease in relation to AF both
in RA and LA tissue [28] and found the AF-associated miR-
NAs only in RA; the lack of detectable AF-associated miR-
NAs in LA may be partially due to lack of tissue availability;
and the study also could not compare the potential diffe-
rences of AF-associated miRNAs between the RA and LA.
Thus, our study is the first to compare the potential
differences of AF-associated miRNAs in the RA and
LA from RMVD patients. We found that the develop-
ment of AF in RMVD patients was associated with sig-
nificant changes in miRNA expression in both RAA
and LAA tissues, and these AF-associated miRNAs had
different distributions in RAA and LAA. A total of 23
AF-associated miRNAs were both in RAA and LAA,
while 45 AF-associated miRNAs were only in RAA, and 19
Table 3 miRNA expression differences between AF-LAA
and SR-LAA
miRNA SR-LAA
signal
AF-LAA
signal
Log2
(AF-LAA/SR-LAA) P-value
Up-regulated (n = 22*)
hsa-miR-3613-3p 294 3063 3.38 1.07E-02
hsa-miR-494 296 1881 2.67 5.89E-02
hsa-miR-3591-3p 539 2069 1.94 7.14E-02
hsa-miR-4485 80 284 1.83 5.03E-02
hsa-miR-574-3p 4478 13516 1.59 2.41E-02
hsa-miR-466 1183 3343 1.50 2.31E-02
hsa-miR-4492 334 834 1.32 2.73E-02
hsa-let-7d-3p 146 344 1.23 9.94E-02
hsa-miR-4707-5p 387 857 1.15 2.92E-02
hsa-miR-4534 79 172 1.12 6.66E-02
hsa-miR-3940-5p 397 803 1.02 5.71E-02
hsa-miR-3178 185 374 1.01 1.97E-02
hsa-miR-15b-5p 383 723 0.92 3.04E-02
hsa-miR-21-5p 442 819 0.89 4.66E-02
hsa-miR-3196 1383 2477 0.84 1.34E-02
hsa-miR-1307-3p 82 145 0.83 5.28E-02
hsa-miR-331-3p 140 247 0.82 6.46E-02
hsa-miR-149-3p 96 163 0.77 6.79E-02
hsa-miR-181a-5p 1057 1613 0.61 8.50E-02
hsa-miR-30a-5p 249 376 0.59 6.94E-02
hsa-miR-1973 745 1123 0.59 6.02E-02
hsa-miR-4497 4574 6546 0.52 4.68E-02
Down-regulated (n =20*)
hsa-miR-1 12740 3079 −2.05 1.94E-02
hsa-miR-26b-5p 794 198 −2.00 2.30E-02
hsa-miR-4454 1262 488 −1.37 3.93E-02
hsa-miR-361-5p 652 259 −1.33 3.53E-02
hsa-miR-151a-5p 694 302 −1.20 3.90E-02
hsa-miR-26a-5p 9702 4314 −1.17 7.22E-03
hsa-miR-378a-3p 683 307 −1.15 7.26E-02
hsa-miR-5190 311 141 −1.14 9.06E-02
hsa-miR-5100 775 363 −1.10 2.89E-02
hsa-miR-151b 609 288 −1.08 6.25E-02
hsa-miR-4442 350 169 −1.05 6.69E-02
hsa-miR-2861 2103 1141 −0.88 6.50E-02
hsa-miR-143-3p 1380 778 −0.83 9.49E-02
hsa-miR-378d 197 112 −0.82 7.07E-02
hsa-miR-23c 939 583 −0.69 8.28E-02
hsa-miR-195-5p 612 385 −0.67 2.21E-02
hsa-miR-720 952 619 −0.62 4.67E-02
Table 3 miRNA expression differences between AF-LAA
and SR-LAA (Continued)
hsa-miR-4281 836 545 −0.62 6.92E-02
hsa-let-7f-5p 10225 7040 −0.54 5.58E-02
hsa-miR-23b-3p 12468 8685 −0.52 7.24E-02
*Expression levels of miRNAs are described as up-regulated or down-regulated
in AF-LAA relative to those in SR-LAA.
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distributions of these AF-associated miRNAs may reflect
different miRNAs mechanisms in AF between the RA
and LA.
miRNA expression profiles are genetically programmed
with temporal patterns (depending on developmental stage
or disease status) [29]. Specific alterations in miRNA ex-
pression profiles are associated with specific disease patho-
physiologies [30]. Our study has shown that AF status
resulted in a larger number of miRNAs expressed as com-
pared to the SR status (Figure 1B) and the AF-associated
miRNAs were found in both RAA (Table 2, Figure 3A) and
LAA (Table 3, Figure 3B) tissues from RMVD patients.
Studies have shown that miRNAs may be involved directly
or indirectly in AF by modulating atrial electrical remodel-
ing (i.e. miR-1, miR-26, and miR-328) or structural remod-
eling (i.e. miR-30, miR-133, and mir-590). Yang et al. [31]
reported that miR-1 overexpression slowed conduction
and depolarized the cytoplasmic membrane by post-
transcriptionally repressing KCNJ2 (potassium inwardly-
rectifying channel, subfamily J, member 2; which encodes
the K
+ channel subunit Kir2.1) and GJA1 (gap junction
protein, alpha 1, 43 kDa; which encodes connexin 43), and
this likely accounts at least in part for its arrhythmogenic
potential. Girmatsion et al. [32] indicated that miR-1 levels
are greatly reduced in human AF, possibly contributing to
up-regulation of Kir2.1 subunits, leading to increased car-
diac inward-rectifier potassium current (IK1). Luo et al.
[13] identified miR-26 as a potentially important regulator
of KCNJ2 gene expression and, via IK1, a determinant of
AF susceptibility. Li et al. [12] reported that miR-133 and
miR-30, as anti-fibrotic miRNAs [33,34], may play an im-
portant role in the control of structural changes in chronic
AF. To date, the miR-23, miR-125, miR-143, miR-145,
miR-4454, and miR-4484 have not been described as
participating in AF pathology. Based on the predictions of
putative target genes and pathways determined using miR-
Focus (Table 6), we have found that these miRNAs are
potentially involved in several important biological pro-
cesses and functional pathways associated with AF (e.g.,
TGF-beta, MAPK, VEGF, Calcium, Gap junction, mTOR,
and Wnt signalling pathway, most of which have been
implicated in the pathogenesis of AF). Thus, our results
may implicate these miRNAs in the pathogenesis of AF.
Table 4 Comparison of AF-associated miRNAs between RAA and LAA
Number AF-associated miRNAs
Both in RAA and
LAA
23 hsa-miR-143-3p, hsa-miR-149-3p, hsa-miR-151a-5p, hsa-miR-151b, hsa-miR-181a-5p, hsa-miR-195-5p, hsa-miR-1973, hsa-miR-21-5p,
hsa-miR-26a-5p, hsa-miR-26b-5p, hsa-miR-2861, hsa-miR-30a-5p, hsa-miR-331-3p, hsa-miR-378a-3p, hsa-miR-378d, hsa-miR-3940-5p,
hsa-miR-428, hsa-miR-4454, hsa-miR-4485, hsa-miR-4497, hsa-miR-4534, hsa-miR-4707-5p, hsa-miR-5100
Only in RAA 42 hsa-let-7a-5p, hsa-miR-107, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-1281, hsa-miR-133b, hsa-miR-145-5p, hsa-miR-152,
hsa-miR-16-5p, hsa-miR-1915-3p, hsa-miR-191-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-22-3p, hsa-miR-25-3p, hsa-miR-
29a-3p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-30d-5p, hsa-miR-3141, hsa-miR-3656, hsa-miR-4284, hsa-miR-4286, hsa-miR-
4298, hsa-miR-4324, hsa-miR-4443, hsa-miR-4459, hsa-miR-4463, hsa-miR-4466, hsa-miR-4484, hsa-miR-4488, hsa-miR-4505,
hsa-miR-4508, hsa-miR-451a, hsa-miR-4530, hsa-miR-455-3p, hsa-miR-4687-3p, hsa-miR-486-5p, hsa-miR-574-5p, hsa-miR-762,
hsa-miR-940, hsa-miR-99a-5p
Only in LAA 19 hsa-let-7d-3p, hsa-let-7f-5p, hsa-miR-1, hsa-miR-1307-3p, hsa-miR-15b-5p, hsa-miR-23b-3p, hsa-miR-23c, hsa-miR-3178,
hsa-miR-3196, hsa-miR-3591-3p, hsa-miR-3613-3p, hsa-miR-361-5p, hsa-miR-4442, hsa-miR-4492, hsa-miR-466, hsa-miR-494,
hsa-miR-5190, hsa-miR-574-3p, hsa-miR-720
Figure 4 Comparison of signal intensities of miRNAs
significantly dysregulated in RAA and LAA tissues. The signal
intensities of miRNAs expressed in the SR group (x-axis) and AF
group (y-axis) were compared. The miRNAs with the higher signal
intensities (>1000 units) either on the x-axis or y-axis were labelled
red. (A) AF-RAA vs SR-RAA. (B) AF-LAA vs SR-LAA.
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grammed with certain spatial characteristics (depending
on cell, tissue, or organ type) [35,36]. For example,
miR-208 and miR-499 are cardiac-specific miRNAs
exclusively expressed in cardiac tissues, while miR-1 and
miR-133 are muscle-specific miRNAs preferentially
expressed in cardiac and skeletal muscle [37,38]. We
have found that the expression levels of most AF-
associated miRNAs were identical between RAA and
LAA tissues in SR patients, with exception of miR-23b-
3p and miR-125b-5p (Figure 6). Thus, we conclude
that most of the AF-associated miRNAs, except miR-
23b-3p and miR-125b-5p, were not tissue dependent
and the different distribution of these miRNAs in RA
and LA is caused by the different mechanisms involved
in AF between RA and LA. Our results have shown
that miR-23b-3p was more highly expressed in the SR-
LAA group than in SR-RAA and was AF-associated
miRNAs only in LAA tissue, while, miR-125b-5p was
more highly expressed in the SR-RAA group than in
SR-LAA and was AF-associated miRNAs only in RAA
tissue. miR-23b-3p and miR-125b-5p are tissue
dependent and they may play a role in the progress
from SR to AF as decided by the initial expression (SR
status) in RAA and LAA. The different expression of
miR-23b-3p and miR-125b-5p between RAA and LAA
in RMVD patients with SR maybe due to RMVD, be-
cause Cooley et al. [28] reported that some miRNAs
expression changes in RA and LA with the develop-
ment of valvular heart disease. In addition, in RMVD
patients, the association between LA size and AF is
well established and LA dilatation is considered both a
cause and consequence of AF [15]. Our results have shown
that LA size of the patients with AF was significantly
greater than patients with SR (Table 1), thus, it is possible
that the significant structural remodelling of the LA also
alters the microRNA expression profiles and cause, at least
in part, the different distributions of AF-associated
miRNAs in the RA and LA from RMVD patients.
The main limitation of this study was the small
number of patients included. This was due, in part,
to the difficulty of finding RMVD patients with SR.
Second, We could not conduct experiments to modu-
late miRNA levels in native human tissues. Hence, the
evidence presented here is not a direct cause and effect
relationship. Furthermore, the exact targets and pathways
Figure 5 Validation of the miRNA microarray data using qRT-PCR. RNU6B was used as an internal control for normalizing the results. Data
are reported as mean± standard deviation for three independent experiments. Statistically significant differences between the two groups are
indicated by *P <0.05, compared with SR-RAA (A) or SR-LAA (B).
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remain elusive and deserve further investigation [19].
Finally, the patients included in this study were a spe-
cific cohort with preserved systolic left ventricular func-
tion and little comorbidity; they were undergoing mitral
valve replacement surgery. Changes identified in this
population may not be representative of other cohort of
populations [32].
Conclusions
We have found the different distributions of AF-associated
miRNAs in the RAA and LAA from RMVD patients. This
may reflect different miRNA mechanisms involved in AF
between the RA and LA. These findings may provide new
insights into the underlying mechanisms of AF in RMVD
patients and provide potential novel mechanism-based
therapeutic strategies for AF.
Figure 6 Comparison of validated AF-associated miRNAs expression level between RAA and LAA in SR status. Data are reported as mean±
standard deviation for three independent experiments, *P <0.05, compared with SR-RAA (A,B,C);* * P <0.05, compared with SR-LAA (B) or SR-RAA (C).
Table 5 Prediction of putative target genes and pathways of the validated miRNAs
miRNAs target gene GO
term
KEGG
pathways
Target prediction database
Total Experimental validated
miR-1 135 68 101 9 miRanda, MirTarget, microT, PicTar, TargetScan
miR-23b-3p 296 8 91 5 miRanda, MirTarget, microT, PicTar, TargetScan
miR-26a-5p 210 7 62 11 miRanda, MirTarget, microT, PicTar, TargetScan
miR-30c-5p 365 5 70 5 miRanda, MirTarget, microT, PicTar, TargetScan
miR-125b-5p 80 5 35 2 miRanda, MirTarget, microT, PicTar, TargetScan
miR-133b 85 3 243 14 miRanda, MirTarget, microT, PicTar, TargetScan
miR-143-3p 51 2 39 24 miRanda, MirTarget, microT, PicTar, TargetScan
miR-145-5p 127 20 82 12 miRanda, MirTarget, microT, PicTar, TargetScan
miR-4454 0 0 0 0 miRanda, MirTarget, microT, PicTar, TargetScan
miR-4484 9 0 74 40 MirTarget, TargetScan
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